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Sir,
Chronic hepatitis C infection affects 170 million individualsworldwide. Since the introduction of new oral directacting antiviral (DAA) drugs, the treatment of chronichepatitis C infection has been revolutionised.1 Althoughmetabolic derangements along with insulin resistanceare widely recognised with HCV infection, there are fewcase reports of how treatment with the newer oralantiviral agents leads to diabetes in previously non-diabetic chronic hepatitis C infected patients, aftersuccessful eradication of the infection itself.2
Here, we describe a case of a 50-year female with abody mass index (BMI) of 32.8 kg/m2 with chronichepatitis C virus infection, mixed genotype 3 and 6,diagnosed and started on three drug regimens withsofosbuvir, 400 mg QD, Daclatasvir Dihydrochloride, 60mg QD, and Ribavarin 400 mg TID. She achieved end-of-treatment response (ETR) at 6 months but thereafterpresented with history of progressive leg pains. Ontesting, her random blood sugar was 494 mg/dl with ananion gap of 12 and no urinary ketones. Prior to startingantiviral agents, her HbA1c was 5.50% and threemonths post-treatment, her HbA1c was 11.40%. HerHbA1c pre- and post-treatment were done by ourlaboratory by immunoturbidity method and data from thislaboratory is traceable to NGSP and is DCCT certified.There was no history of gestational diabetes mellitus(DM) or pre-diabetes, except that her father was aknown diabetic. Other etiologies for her raised bloodsugars were excluded, including exposure to certaindrugs, pancreatitis or any ongoing acute infection.
In recent past, there has accumulated conflicting data oneffects of oral DAAs with few studies favouring good
glycemic control following treatment; whereas, othersshowing no effects on HbA1c levels pre- and post-treatment.3,4 Our patient did not have any comorbities ora pre-diabetic range HbA1c level prior to treatment withDAAs and it was only after completion of treatment andachieving ETR that there was a sudden rise in HbA1clevels. Therefore, we could not completely rule out thepossibility that the DAAs might have led to overthyperglycemia in our patient or this could simply be acoincidence. It is not possible to pinpoint the precipitatingfactor on the basis of just one case presented here.However, it provides food for thought for future studieson this subject.
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